Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 17, 2026

New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test

View original at finance.yahoo.com
New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test Data show how a multi-biomarker class approach improves early-stage cancer detection AACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical impact of MCED ABBOTT PA…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Cancerguard is currently the only commercially available MCED test designed with a multi-biomarker class approach, combining methylation and protein signals to improve detection

    60% confidence

  • DETECT-A study identified nine cancer types, including several without routine screening, and showed that after median follow-up of approximately four years, all patients treated for stage I or II cancers remained alive and cancer-free

    60% confidence

  • By combining biomarkers, Abbott can detect cancer earlier, when it matters most

    60% confidence

  • Cancerguard was designed as the first-of-its-kind multi-biomarker test because no one signal tells the whole story

    60% confidence

Cited in these Via News reports